<DOC>
	<DOCNO>NCT00096629</DOCNO>
	<brief_summary>RATIONALE : Vaccines make DNA may make body build immune response kill tumor cell . PURPOSE : This randomized phase I trial study side effect best dose vaccine therapy treat patient kidney cancer .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety feasibility vaccination human mouse prostate-specific membrane antigen ( PSMA ) DNA patient renal cell carcinoma . - Determine maximum tolerate dose regimen patient . - Determine antibody responses human PSMA patient treat regimen . Secondary - Assess antitumor response patient treat regimen . OUTLINE : This randomize , dose-escalation study . Patients randomize 1 2 treatment arm . - Arm I : Patients receive human prostate-specific membrane antigen ( PSMA ) DNA vaccine intramuscularly ( IM ) every 3 week 3 dos ( dose 1-3 ) . Patients receive mouse PSMA DNA vaccine IM every 3 week 3 dos ( dose 4-6 ) . - Arm II : Patients receive mouse PSMA DNA vaccine IM every 3 week 3 dos ( dose 1-3 ) . Patients receive human PSMA DNA vaccine IM every 3 week 3 dos ( dose 4-6 ) . In arm , treatment continue absence disease progression unacceptable toxicity . Patients stable respond disease may receive additional booster vaccination second form PSMA DNA vaccine receive ( dos 4-6 ) every 8 week 4 additional dos . Cohorts 3-6 patient per arm receive escalate dos human mouse PSMA DNA vaccine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Patients follow every 3 month 2 year .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm renal cell carcinoma Patients minimal disease burden eligible provide meet one follow criterion : Prior nephrectomy completely resect metastasis Favorablerisk group , define follow criterion : Karnofsky 80100 % Hemoglobin ≥ 13 g/dL ( male ) ≥ 12 g/dL ( female ) Corrected calcium ≤ 10 mg/dL Prior nephrectomy Serum lactate dehydrogenase ≤ 200 μ/L Prior nephrectomy metastasis confine lung and/or small volume metastatic disease ( &lt; 3 cm ) exclusive bone liver No spinal , epidural , CNS lesions No bone , liver brain disease PATIENT CHARACTERISTICS : Age 18 Performance status See Disease Characteristics Karnofsky 80100 % Life expectancy Not specify Hematopoietic See Disease Characteristics WBC ≥ 3,500/mm^3 Hemoglobin ≥ 12.0 g/dL Platelet count ≥ 100,000/mm^3 Hepatic Bilirubin &lt; 2.0 mg/dL SGOT &lt; 3.0 time upper limit normal Renal See Disease Characteristics Creatinine ≤ 2.0 mg/dL OR Creatinine clearance ≥ 40 mL/min Cardiovascular No clinically significant cardiac disease No New York Heart Association class III IV heart disease Pulmonary No severe debilitate pulmonary disease Other Fertile patient must use effective contraception No active secondary malignancy within past 5 year except nonmelanoma skin cancer No infection require antibiotic treatment No narcotic steroiddependent pain PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy At least 4 week since prior chemotherapy Endocrine therapy At least 4 week since prior corticosteroid therapy Radiotherapy At least 4 week since prior radiotherapy No concurrent radiotherapy measurable lesion Surgery See Disease Characteristics No concurrent surgery Other Recovered prior therapy No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>stage I renal cell cancer</keyword>
	<keyword>stage II renal cell cancer</keyword>
	<keyword>stage III renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
</DOC>